hema.to closes third financing round

hema.to has closed a €3.6 million financing round led by LUMO Labs, an impact-driven Dutch venture capital firm. This financing will help hema.to pursue product-market fit for its clinical-grade AI software for blood cancer and other cytometry-based blood tests.

hema.to’s committed investors include Elaia and Clément Vanden Driessche, Heal Capital and Christian Lautner, HTGF | High-Tech Gründerfonds and Dr. Nik Raupp, Labor Becker MVZ eGbR, Marc Becker, Malte von Trotha, and angel investor Thomas Henkel.

New investors include Bayern Kapital and Matthias Buchinger, Cross Atlantic Angels with Jens Weitzel and Niklas Herriger, and Akwa Group with Pim Hollestelle and Thomas Hannes.

The round strengthens hema.to’s work to build innovative cytometry technology that supports earlier diagnoses and better treatment decisions.